Authors
Latest:
Fezolinetant Changes Menopause Management, with JoAnn Vensko Pinkerton, MDPinkerton reflects on the breakthrough approval for the non-estrogen, non-hormonal daily oral drug earlier this year.
Latest:
SEQUENCE: Comparing Risankizumab to Ustekinumab in Crohn’s DiseaseUstekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.
Latest:
The Future of IgA Nephropathy TreatmentJonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.
Latest:
Tips to Optimize Care for Patients With Ulcerative ColitisAdvice for community physicians and gastroenterologists to help manage patients with ulcerative colitis.
Latest:
Risk-Benefit of Geographic Atrophy TreatmentDavid Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.
Latest:
The Future of Treatment for Diabetic Macular EdemaDr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.
Latest:
Measuring Patient Satisfaction with Inflammatory Bowel Disease Treatments and Communication Regarding Treatment ChangesSilvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, conclude by sharing their approaches to evaluating patient satisfaction and expectations when providing care for ulcerative colitis and Crohn's disease, while also touching upon the importance of discussing the potential need for escalating or switching therapies to better manage the underlying disease processes.
